Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hologic Growth Aided By 3D Mammography System Sales Overseas

This article was originally published in The Gray Sheet

Executive Summary

Women’s health firm Hologic reported 13.1% growth in its breast health segment in its fiscal fourth quarter, to $197.7 million, aided in part by overseas sales of its Selenia Dimensions three-dimensional digital mammography system, the firm announced Nov. 8.

You may also be interested in...



Digital Mammography Systems Are Now 510(k) Products – FDA Final Rule

Two-dimensional digital mammography systems, such as those made by Hologic and GE Healthcare, can now enter the market through the 510(k) versus PMA route, according to a final rule and special controls guidance issued Nov. 4.

Hologic Looks Ahead To Reimbursement, Training For 3D Mammography

Hologic is already looking ahead to reimbursement and training requirements for its Selenia Dimensions 3D three-dimensional digital mammography system as it works with FDA on final pre-market approval issues, the company says

Hologic Selenia 3D Digital Mammography System Gets Panel Nod

FDA's Radiological Devices Advisory Panel unanimously endorsed safety and efficacy data on Hologic's Selenia Dimensions 3D three-dimensional digital mammography system for screening and diagnosis of breast cancer at a Sept. 24 meeting

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel